Drug Trial Radar · NCT00236782
A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.
Last checked: Nov 20, 2026Latest source record: Jun 8, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,517
Actual
Start
Oct 1997
Primary completion
Not stated
Study completion Mar 1999
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study was to compare the contraceptive efficacy and safety of the transdermal patch to Mercilon.
Conditions
- Contraception
Interventions
norelgestromin + ethinyl estradiol; mercilonDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Contraceptive efficacy of the 2 treatments was estimated by determination of pregnancy rates, using the Pearl Index and life table analysis (cumulative probability of pregnancy). Safety was evaluated throughout the study.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.